Alvotech
Alvotech is a global biopharmaceutical company, focused on developing biosimilar versions of leading monoclonal antibodies molecules.
Total raised
€143M
€143,000,000
Funding rounds
2
Investors
2
distinct backers
Active since
2018-12
latest 2026-01
Funding by year
EUR raised per year · 2026 YTDSignals
High confidenceRaise-next likelihood55
base rate 45% for Debt
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood20
base rate 12% (2+ rounds)
- ▲ €100M+ raised
- ▲ 13y since founding
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-01-02 | Debt | €100M | GoldenTree Asset Management | View deal → |
| 2019-01-01 | Other | €43M | Fuji Pharma | View deal → |
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Oura Health€779MFinland · Healthtech
- Doctolib€734MFrance · E-commerce